← Back to Clinical Trials
Recruiting NCT06679491

NCT06679491 Impact of Menstrual Cycle-Based Resistance Training on Neuromuscular Performance in Female Athletes

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06679491
Status Recruiting
Phase
Sponsor Universite de La Reunion
Condition Menstrual Cycle
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2024-11-01
Primary Completion 2025-07-01

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Resistance periodized training program (N-PF)Resistance peioridized training program (N-PL)Continuous resistance training program (C)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2024-11-01 with a primary completion date of 2025-07-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to assess the impact of menstrual cycle-based resistance training on neuromuscular function in female athletes. The primary questions it aims to answer are : * Does varying resistance training intensity according to menstrual phases improve maximal knee extensor strength? * How do different training protocols affect voluntary activation, rate of force development, muscle stiffness, and vertical jump height? Researchers will compare natural menstrual cycle groups with an oral contraceptive control group to determine if menstrual phase-specific training influences neuromuscular adaptations. Participants will: * Undergo 2 weekly resistance training sessions over 13 weeks with intensity adjustments based on menstrual phase * Complete periodic neuromuscular assessments across three menstrual phases: early follicular, late follicular, and mid-luteal before and after resistance training intervention

Eligibility Criteria

Inclusion Criteria: * Female athletes with natural menstrual cycles (eumenorrheic): Participants must have regular menstrual cycles lasting between 21 and 35 days, with at least 9 cycles per year. * Women using a low-dose monophasic estrogen-progestin oral contraceptive. * Age 18 or older: Participants must be legal adults. * Body Mass Index (BMI) between 18 and 30 kg/m². * No medical contraindications to high-level physical training or exercise. * Physically active: Engages in at least 3 hours of physical activity per week. * Informed consent: Provides written, informed consent to participate in the study. * Affiliation with a social security system (if applicable by local regulations). Exclusion Criteria: \-

Contact & Investigator

Central Contact

Manon DAUVERGNE, PhD student

✉ manon.dauvergne@univ-reunion.fr

📞 +262693463288

Principal Investigator

Nicolas PEYROT, Professor (PU)

STUDY DIRECTOR

Université du Mans

Frequently Asked Questions

Who can join the NCT06679491 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Menstrual Cycle. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06679491 currently recruiting?

Yes, NCT06679491 is actively recruiting participants. Contact the research team at manon.dauvergne@univ-reunion.fr for enrollment information.

Where is the NCT06679491 trial being conducted?

This trial is being conducted at Le Tampon, Reunion.

Who is sponsoring the NCT06679491 clinical trial?

NCT06679491 is sponsored by Universite de La Reunion. The principal investigator is Nicolas PEYROT, Professor (PU) at Université du Mans. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology